84 yo F #HOCM with resting LVOT MG 122 mmHg on Mavacamten 10 mg nebivolol 5 mg. Cath rest PG 127 and post PVC PG 210 mmHg. Turned down for septal myectomy. ASA vs SESAME? #CardioTwitter Srihari S. Naidu, MD Adam Greenbaum Jaffar Khan Jamie McCabe Isida Byku MD Vasilis Babaliaros

⁦Milind Desai MD MBA⁩ presents work that mavacamten significantly improves quality of life in obstructive hypertrophic cardiomyopathy patients as measured by Kansas City Cardiomyopathy Questionnaire (KCCQ). ⁦American College of Cardiology⁩ ⁦HFSA⁩ #ACC23

#EchoLucerne Day 2: Prof. Gruner - #mavacamten & #HCM : remodeling & functional improvement in HCM - cineloops by Prof. iacopo olivotto 🫀

Dept. of Cardiology - University Hospital Zurich European Society of Cardiology, & AHA Science/American College of Cardiology
ESC President HFAPresident Simon Stämpfli SwissCOT Swiss Societey of Hypertension Unisanté (compte inactif) MarjamRüdiger@SSC…

ESC心筋症ガイドラインが9年ぶり改定。ついにミオシン阻害薬Mavacamtenがガイドラインに登場。
#ESCCongress2023
#escardio

Los '12 caballeros' de la IC.💊👑
✅️Son bien conocidos los 4 pilares de Tto de la IC (ARNi, BB, iSGLT2, ARM), pero existen otras opciones terapéuticas con evidencia a su favor (⤵️☠️🏥).
✅️Aquí un repaso enfocado en Veraciguat, Omecamtiv mecarbil, Aficamten/Mavacamten.. 🧐✍️💯

🔴We are delighted to announce the acceptance of our abstract, 'Efficacy and safety of mavacamten for the treatment of hypertrophic cardiomyopathy: an updated systematic review and meta-analysis of randomized controlled trials' in the ACC Scientific Session 2024.

Myosin inhibitors for HCM? Negative inotropes are standard of care for obstructive HCM. If medical therapy fails, surgical myomectomy can relieve symptoms. This trial showed mavacamten (a novel actin-myosin binding inhibitor) to reduce surgical need. VALOR-HCM Trial, JACC 2022 ♥️

Myosin inhibitors for obstructive HCM? Negative inotropes are standard of care, but at times fail. This trial showed mavacamten (an actin-myosin binding inhibitor) to reduce outflow tract gradient and further improve symptoms. EXPLORER-HCM Trial, NEJM 2020 ♥️

So happy to be the 1st center in Europe to use this groundbreaking drug for #hcm pts.
However:
- challenging monitoring + titration process
- careful planning of pts visits + echo needed.
- Real world data needed !
#mavacamten #myosininhibitors

Dr. Andrew Wang and I discuss the long-term safety of mavacamten. We also cover the recommended dosing and real-world evidence around appropriate dose titration.

I am immensely proud Essex ICC is one of the first centres in the UK to prescribe Mavacamten, the new and exciting first-in-class treatment for inherited heart condition Hypertrophic Cardiomyopathy 😀
First 2 patients started this month ✅🙌🏾
(posted with permission)
#Trailblazers

Mavacamten: Practical Answers for the Clinician and New Questions From the MAVA–Long-Term Extension Study
#Editorial JACC Journals

jacc.org/doi/10.1016/j.…
#Cardiology #CardioTwitter #CardioEd

Great lecture w. Anjali Owens Re: HCM
💥Cardiac myosin inhibitors & SRT improve symptoms, quality of life, exercise tolerance, reducing LVOT gradient in oHCM
💥Mavacamten FDA-approved TX symptomatic oHCM
💥CMIs require safety monitoring of LVEF due to risk of systolic dysfunction

Our paper is now in nature: #CryoEM 6 Å reconstruction of #human cardiac thick filament C-zone in #mavacamten , showing #myosin heads, tails, #titin , #MyBP -C. Many implications for a 60-year mystery on #cardiac #muscle #physiology , #structure and #disease .
shorturl.at/mwU16

Dr. Richard Wright and I discuss the first and only approved cardiac myosin inhibitor, mavacamten! We discuss the efficacy of this paradigm shifting agent through the EXPLORER, VALOR, long term extension studies as well as real-world experience. Part 1

Excited for our new #CryoEM reconstruction of #human cardiac thick filament C-zone in #mavacamten , showing #myosin heads, tails, #titin and #MyBP -C at 6 Å resolution. Many implications for #cardiac #muscle #physiology , #structure and #disease .
shorturl.at/fjy05

📯Excited to share the first Real 🌍 post Trial Experience (n=23) of Mavacamten in Obstructive HCM‼️led by Matthew W Martinez 🖨️ JACC Journals
At 7 months,
➡️ Mavacamten led to sustained ⬇️ LVOT gradients at Rest/Valsalva with no change in LVEF
➡️ EKG normalization in 21% of oHCM

Heart2Heart stage now!
Co-chaired by Dr. Purvi Parwani
- clinical application on mavacamten in obstructive HCM
- will the drug ⬇️ CT surgery?
- can we use is for diagnosis?
- are there drug-drug interactions?
Answers to these Qs and May more with Dr. Desai! American College of Cardiology #acc23

Our structures of the #cardiac #sarcomere are now published in nature! With #teamtomo at @intein lab, we've used #CryoET to unveil how #myosin and #actin filaments arrange in #muscle relaxed with #mavacamten . Great collaboration with Gautel Lab!
doi.org/10.1038/s41586… 🧵

Had a fun time connecting & learning more about hypertrophic cardiomyopathy🫀and the current data & use of mavacamten.

Thank you Srihari S. Naidu, MD! We appreciate you!

New York Chapter, ACC #Cardiology #CardioTwitter